» Articles » PMID: 34440315

Nitric Oxide Synthase Dependency in Hydroxyurea Inhibition of Erythroid Progenitor Growth

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2021 Aug 27
PMID 34440315
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hydroxyurea (HU) causes nitric oxide (NO) bioactivation, acting as both a NO donor and a stimulator of NO synthase (NOS). To examine whether HU effects are NO mediated by chemical degradation or enzymatic induction, we studied human and mouse erythroid cells during proliferation, apoptosis, and differentiation. The HU and NO donor demonstrated persisted versus temporary inhibition of erythroid cell growth during differentiation, as observed by γ- and β-globin gene expression. HU decreased the percentage of erythroleukemic K562 cells in the G2/M phase that was reversed by N-nitro l-arginine methyl ester hydrochloride (L-NAME). Besides activation of endothelial NOS, HU significantly increased apoptosis of K562 cells, again demonstrating NOS dependence. Administration of HU to mice significantly inhibited colony-forming unit-erythroid (CFU-E), mediated by NOS. Moreover, burst-forming-units-erythroid (BFU-E) and CFU-E ex vivo growth was inhibited by the administration of nitrate or nitrite to mice. Chronic in vivo NOS inhibition with L-NAME protected the bone marrow cellularity despite HU treatment of mice. NO metabolites and HU reduced the frequency of NOS-positive cells from CFU-E and BFU-E colonies that was reverted by NOS inhibition. HU regulation of the G2/M phase, apoptosis, differentiation, cellularity, and NOS immunoreactive cells was NOS dependent. Inhalation of NO therapy as well as strategies to increase endogenous NO production could replace or enhance HU activity.

Citing Articles

The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease.

Belcher J, Nataraja S, Abdulla F, Zhang P, Chen C, Nguyen J Front Med (Lausanne). 2023; 10:1101501.

PMID: 37144034 PMC: 10152901. DOI: 10.3389/fmed.2023.1101501.


Nitric Oxide Mediation in Hydroxyurea and Nitric Oxide Metabolites' Inhibition of Erythroid Progenitor Growth.

Suboticki T, Ajtic O, Djikic D, Kovacic M, Santibanez J, Tosic M Biomolecules. 2021; 11(11).

PMID: 34827560 PMC: 8616001. DOI: 10.3390/biom11111562.

References
1.
Gladwin M, Shelhamer J, Ognibene F, Nichols J, Link B, Patel D . Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002; 116(2):436-44. DOI: 10.1046/j.1365-2141.2002.03274.x. View

2.
Almeida C, Scheiermann C, Jang J, Prophete C, Costa F, Conran N . Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood. 2012; 120(14):2879-88. PMC: 3466969. DOI: 10.1182/blood-2012-02-409524. View

3.
Sakano K, Oikawa S, Hasegawa K, Kawanishi S . Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res. 2001; 92(11):1166-74. PMC: 5926660. DOI: 10.1111/j.1349-7006.2001.tb02136.x. View

4.
Reykdal S, Abboud C, Liesveld J . Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Exp Hematol. 1999; 27(3):441-50. DOI: 10.1016/s0301-472x(98)00030-7. View

5.
Lemaire G, Beuneu C, LEPOIVRE M, PETIT J . Differential cytostatic effects of NO donors and NO producing cells. Free Radic Biol Med. 1999; 26(9-10):1274-83. DOI: 10.1016/s0891-5849(98)00331-1. View